• Biotech Snap
  • Posts
  • Alfasigma bets up to $690M on GSK’s PBC itch drug & Roche's breast cancer drug fails Phase 3

Alfasigma bets up to $690M on GSK’s PBC itch drug & Roche's breast cancer drug fails Phase 3

AuthorAuthor

Joachim Eeckhout & Eduardo Longoria
March 10, 2026

Good morning! Paris-based kyron.bio has partnered with Servier to test whether it can more precisely control the sugar molecules attached to an antibody. Those sugars can affect how well an antibody works, how stable it is, and how consistently it can be made. Under the deal, kyron.bio will do the research, Servier will fund it and has the option to expand the collaboration if the results are promising. Financial terms weren’t disclosed.

Why it matters: In antibody manufacturing, those sugar patterns are usually a byproduct of the manufacturing process, not something drugmakers can precisely choose. kyron.bio’s pitch is that tighter control could turn that variability into a design advantage.

Bottom line: Glycosylation is starting to look like a product strategy, not just a chemist's talking point.

— Joachim E.

Don’t keep this newsletter a secret: Forward Biotech Snap to a friend!

Was this email forwarded to you? Sign up here.

SNAPSHOT

Alfasigma bets up to $690M on GSK’s late-stage PBC itch drug

Scratch my ear, dog,

Why it matters: If approved, linerixibat could become the first therapy specifically designed to relieve severe itching in PBC patients, an often debilitating symptom that current disease treatments do not reliably address.

Backstory: PBC is a chronic autoimmune liver disease that disrupts bile flow. The resulting buildup of bile acids is believed to trigger cholestatic pruritus, intense internal itching that affects up to 90% of PBC patients and can severely impair sleep and quality of life. Existing PBC drugs mainly target the underlying disease rather than this symptom.

Big picture: The deal reflects a strategic shift for both companies. Alfasigma is expanding its hepatology franchise after acquiring Intercept Pharmaceuticals in 2023, which brought the PBC drug Ocaliva into its portfolio. Meanwhile, GSK is prioritizing larger liver disease opportunities and offloading commercialization of this asset to a partner already focused on PBC.

Zoom in: Structured with a $300M upfront payment to GSK, the deal offers a further $100M if the FDA approves the drug. Contingent on the approval of the drug in Europe and the U.K., a further $20M can be added onto the $270M in sales milestones and tiered double-digit royalties on global sales.

What’s next: The FDA is expected to decide on approval on March 24, 2026. Reviews are also underway in the EU, U.K., China (priority review), and Canada.

Yes, but: Competition is emerging. Mirum Pharmaceuticals is developing another IBAT inhibitor, volixibat, for PBC-related pruritus, but its phase 3 data are not expected until 2027, potentially giving linerixibat a first-mover advantage if approved.

SNIPPETS

What’s happening in biotech today?

🧬 SERD doubts: Roche announced that its experimental breast cancer drug giredestrant failed to meet the main goal of a Phase 3 trial testing it as a first-line treatment in combination with Pfizer’s Ibrance. The combo did not significantly delay disease progression or death compared with Ibrance plus standard hormone therapy. The result weakens Roche’s hopes that the drug could become a new treatment standard and a potential multibillion-dollar product. The setback also raises broader doubts about the effectiveness of oral SERDs, a drug class that currently includes Menarini’s Orserdu and Eli Lilly’s Inluriyo, which are approved only for certain mutation-driven cancers. Meanwhile, competitors such as AstraZeneca’s camizestrant are advancing with promising trials and ongoing regulatory review.

📈 Stock pop: Xenon Pharmaceuticals reported strong Phase 3 results for its epilepsy drug azetukalner, which significantly reduced focal seizure frequency in the X-Tole2 trial by 53.2% at a 25 mg dose and 34.5% at 15 mg, compared with about 10% for placebo. The results exceeded analyst expectations and suggest the drug could become a leading treatment for epilepsy due to its effectiveness, tolerability, and compatibility with other medications. The most common side effect was dizziness, with higher discontinuation rates at the higher dose. Following the announcement, Xenon’s stock jumped more than 40%, and the company plans to submit the drug for FDA approval in the third quarter of 2026.

🇨🇳 China deal: And talking about epilepsy, China-based Tenacia Biotechnology signed a deal worth up to $308 million in milestones plus $20 million upfront to license Rapport Therapeutics’ epilepsy drug candidate RAP-219 for development and commercialization in greater China, while Rapport retains rights elsewhere. RAP-219, a potential first-in-class TARPγ8-specific AMPA receptor modulator, is being developed for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. The drug previously showed promising Phase 2a results in drug-resistant epilepsy, significantly reducing seizure episodes, and a global Phase 3 program is expected to begin in Q2, including sites in China run by Tenacia. The partnership aims to accelerate development and expand patient access in China, leveraging Tenacia’s clinical network.

 🧴 Triple threat: Pfizer reported positive Phase 2 results for its trispecific antibody tilrekimig in adults with moderate-to-severe atopic dermatitis (eczema), showing significantly more patients achieved a 75% reduction in disease severity (EASI-75) at Week 16 compared with placebo. Response rates reached 38.7%, 51.9%, and 49.4% across low-, medium-, and high-dose groups, results that appear competitive with the current standard treatment, Dupixent. Tilrekimig targets IL-4, IL-13, and TSLP, potentially improving efficacy by blocking multiple inflammatory pathways. The drug was generally well tolerated, and Pfizer plans to launch a Phase 3 trial this year while also studying it in asthma and COPD, expanding its development across inflammatory diseases.

SPEED READ

More news

TOUR OPERATOR

Upcoming events

What did you think of today's newsletter?

Your feedback helps us create the best newsletter possible.

Login or Subscribe to participate in polls.

Share the Snap!

Know someone who’d enjoy this? Hit forward and pass it along.